Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats

References

• Wesseling C, van Wendel de Joode B, Ruepert C, Leon C, Monge P, Hermosillo H, . Paraquat in developing countries. Int J Occup Environ Health 2001; 7:275–286.
   PubMedGoogle Scholar
• Wesseling C, Hogstedt C, Picado A, Johansson L. Unintentional fatal paraquat poisonings among agricultural workers in Costa Rica: report of 15 cases. Am J Ind Med 1997; 32:433–441.
   PubMed Web of Science ®Google Scholar
• Suntres ZE. Role of antioxidants in paraquat toxicity. Toxicology 2002; 180:65–77.
   PubMed Web of Science ®Google Scholar
• Ghaffari AR, Noshad H, Ostadi A, Hasanzadeh N. Effect of pulse therapy with glucocorticoid and cyclophosphamide in lung fibrosis due to paraquat poisoning in rats. Saudi Med J 2011; 32:249–253.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Srinivas R, Aggarwal AN, Gupta D. Immunosuppressive therapy in lung injury due to paraquat poisoning: a meta-analysis. Singapore Med J 2007; 48:1000–1005.
   PubMedGoogle Scholar
• Bateman DN. Pharmacological treatments of paraquat poisoning. Hum Toxicol 1987; 6:57–62.
   PubMedGoogle Scholar
• Moon JM, Chun BJ. The efficacy of high doses of vitamin C in patients with paraquat poisoning. Hum Exp Toxicol 2011; 30:844–850.
   PubMed Web of Science ®Google Scholar
• Redetzki HM, Wood CD, Grafton WD. Vitamin E and paraquat poisoning. Vet Hum Toxicol 1980; 22:395–397.
   PubMedGoogle Scholar
• Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, . Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002; 23:203–211.
   PubMed Web of Science ®Google Scholar
• Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20:85–97.
   PubMedGoogle Scholar
• Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, . Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821–829.
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, . Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040–1047.
   PubMed Web of Science ®Google Scholar
• Lin X, Yu M, Wu K, Yuan H, Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2009; 50:3763–3770.
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2:111–119.
   PubMed Web of Science ®Google Scholar
• Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci 2003; 75:169–180.
   PubMed Web of Science ®Google Scholar
• Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999; 18:169–177.
   PubMedGoogle Scholar
• Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, . Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001; 14:453–460.
   PubMed Web of Science ®Google Scholar
• Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41:467–470.
   PubMed Web of Science ®Google Scholar
• Li JW, Shen XW, Sun W, Xiao M, Tong SH, Yu XC, . [The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2011; 29:87–93 (abstract).
   PubMedGoogle Scholar
• Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998; 20:685–695.
   PubMed Web of Science ®Google Scholar
• Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol 2008; 8: 679–687.
   PubMed Web of Science ®Google Scholar
• Zheng MH, Dai MS, Lin LF. [Increased expression of placenta growth factor in lung tissue of paraquat-induced rat pulmonary fibrosis model]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2007; 25:527–531.
   PubMedGoogle Scholar
• Yeh ST, Guo HR, Su YS, Lin HJ, Hou CC, Chen HM, . Protective effects of N-acetylcysteine treatment post acute paraquat intoxication in rats and in human lung epithelial cells. Toxicology 2006; 223:181–190.
   PubMed Web of Science ®Google Scholar
• Li LR, Sydenham E, Chaudhary B, You C. Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis. Cochrane Database Syst Rev 2010; CD008084.
   Web of Science ®Google Scholar
• Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009; 2:103–121.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199–210.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Tanaka K, Lim H, Moriyama M. Mechanism of cytotoxicity of paraquat. Environ Health Prev Med 2002; 7:89–94.
   PubMedGoogle Scholar
• Salazar-Montes A, Ruiz-Corro L, Lopez-Reyes A, Castrejon-Gomez E, Armendariz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 2008; 595:69–77.
   PubMed Web of Science ®Google Scholar
• van den Blink B, Jansen HM, Peppelenbosch MP. Idiopathic pulmonary fibrosis: molecular mechanisms and possible therapeutic strategies. Arch Immunol Ther Exp (Warsz) 2000; 48:539–545.
   PubMedGoogle Scholar
• Fabisiak JP, Kagan VE, Tyurina YY, Tyurin VA, Lazo JS. Paraquat-induced phosphatidylserine oxidation and apoptosis are independent of activation of PLA2. Am J Physiol 1998; 274:L793–L802.
   PubMed Web of Science ®Google Scholar
• Yang W, Tiffany-Castiglioni E. Paraquat-induced apoptosis in human neuroblastoma SH-SY5Y cells: involvement of p53 and mitochondria. J Toxicol Environ Health A 2008; 71:289–299.
   PubMed Web of Science ®Google Scholar
• Peng J, Mao XO, Stevenson FF, Hsu M, Andersen JK. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 2004; 279: 32626–32632.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim JE, Moon IS. Paraquat induces apoptosis of cultured rat cortical cells. Mol Cells 2004; 17:102–107.
   PubMed Web of Science ®Google Scholar
• Li X, Sun AY. Paraquat induced activation of transcription factor AP-1 and apoptosis in PC12 cells. J Neural Transm 1999; 106:1–21.
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005; 79:419–426.
   PubMed Web of Science ®Google Scholar
• Cappelletti G, Maggioni MG, Maci R. Apoptosis in human lung epithelial cells: triggering by paraquat and modulation by antioxidants. Cell Biol Int 1998; 22:671–678.
   PubMed Web of Science ®Google Scholar
• Bus JS, Aust SD, Gibson JE. Lipid peroxidation: a possible mechanism for paraquat toxicity. Res Commun Chem Pathol Pharmacol 1975; 11:31–38.
   PubMedGoogle Scholar
• Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000; 204:119–126.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 289:211–218.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291:367–373.
   PubMed Web of Science ®Google Scholar